Αναρτημένες Ανακοινώσεις

Σε Εθνικά Συνέδρια

  1. Τυχαιοποιημένη μελέτη φάσης ΙΙΙ του συνδυασμού ιρινοτεκάνης/ γεμσιταβίνης έναντι γεμσιταβίνης σε ασθενείς με τοπικά εκτεταμένο ή μεταστατικό καρκίνο παγκρέατος

    Γ Σταθόπουλος, Γ Αραβαντινός, Κ Συρίγος, Κ Καλμπάκης, Ν Καρβούνης, Π Παπακοτούλας, Ι Μπουκοβίνας, Α Ποταμιάνου, Α Πολύζος, Χ Χριστοφυλλάκης, Σ Γιασσάς, Ν Βαρδάκης, Ζ Σαριδάκη, Β Γεωργούλιας
    2ο Αντικαρκινικό Συμπόσιο, Μάρτιος 2005

  2. Συνδυασμός ιρινοτεκάνης (CPT-11) και οξαλιπλατίνας (LOHP) σαν θεραπεία 1ης γραμμής σε ασθενείς με τοπικά εκτεταμένο ή μεταστατικό γαστρικό καρκίνο: μια πολυκεντρική μελέτη φάσης ΙΙ

    Λ Βαμβακάς, Ι Σουγκλάκος, Α Ποταμιάνου, Α Πολύζος, Ι Μπουκοβίνας, Ν Ανδρουλάκης, Χ Κουρούσης, Ζ Σαριδάκη, Ν Βαρδάκης, Σ Γιασσάς, Χ Χριστοφυλλάκης, Α Κωτσάκης, Β Γεωργούλιας
    12ο Παγκρήτιο Ιατρικό Συνέδριο, Οκτώβριος 2004

  3. Αρχικά αποτελέσματα μιας πιλοτικής φάσης ΙΙ χορήγησης chronomodulated FOLFOX σαν θεραπεία διάσωσης σε προθεραπευμένους ασθενείς με μεταστατικό καρκίνο παχέος εντέρου as salvage treatment for pretreated patients with metastatic colorectal cancer

    Ι Σουγκλάκος, Δ Τσέτης, Ν Ανδρουλάκης, Θ Κοκκινάκης, Ζ Σαριδάκη, Ν Κατσούγκρης, Χ Κουρούσης, Ν Βαρδάκης, Μ Ιγνατιάδης, Β Γεωργούλιας
    12ο Παγκρήτιο Ιατρικό Συνέδριο, Οκτώβριος 2004

  4. Αστάθεια μικροδορυφορικού DNA (MSI) σε ασθενείς με καρκίνο παχέος εντέρου που έχουν υποβληθεί σε θεραπεία με το συνδυασμό ιρινοτεκάνης (CPT-11), οξαλιπλατίνας (L-OHP) και 5-φλουορουρακίλης/Λευκοβορίνης (Σχήμα DeGramont): συσχετισμός της αστάθειας αλληλουχίας με κλινικές παραμέτρους και θεραπευτική έκβαση

    Ζ Σαριδάκη, Ι Σουγκλάκος, Μ Τσαρδή, Δ Παπαδάτος, Μ Περάκη, Δ Μαυρουδής, Β Γεωργούλιας
    12ο Παγκρήτιο Ιατρικό Συνέδριο, Οκτώβριος 2004

  5. Οξαλιπλατίνα (LOHP) σε συνδυασμό με ιρινοτεκάνη (CPT-11), λευκοβορίνη (LV) και 5-φλουορουρακίλη (5-FU) (FOLFOXIRI) έναντι CPT-11, LV and 5- FU (FOLFIRI) σαν θεραπεία 1ης γραμμής στο μεταστατικό καρκίνο παχέος εντέρου: Αρχικά αποτελέσματα ασφάλειας και δραστικότητας μιας πολυκεντρικής τυχαιοποιημένης κλινικής μελέτης

    Ι Σουγκλάκος, Σ Κακολύρης, Χ Κουρούσης, Ν Ανδρουλάκης, Ν Βαρδάκης, Λ Βαμβακάς, Π Καφαράκης, Γ Ροδιτάκης, Ζ Σαριδάκη, Β Γεωργούλιας
    11ο Παγκρήτιο Ιατρικό Συνέδριο, Χανιά, Νοέμβριος 2003

  6. Ανάλυση 91 περιπτώσεων με οξύ διαρροϊκό σύνδρομο

    Καζάκου Ε, Παπαδημητράκη Ε, Μιξάκη Ι, Σαριδάκη Ζ, Καφαράκης Π, Λαζαρίδου Σ, Ρέππα Δ, Κοφτερίδης Δ
    8ο Πανελλήνιο Συνέδριο Παθολογίας, Αθήνα, Οκτώβριος 2002 Δημοσίευση abstract – Νοσοκομειακά Χρόνια, Τόμος Περιλήψεων Εργασιών, Τόμος 64, Συμπλήρωμα 2002, #45, σ53, Οκτώβριος 2002

  7. Λοιμώξεις σε διαβητικούς ασθενείς

    Κοφτερίδης Δ, Σαριδάκη Ζ, Παπαδημητράκη Ε, Καζάκου Ε, Μυξάκη Ι, Φάντη Γ, Γανωτάκης Ε
    8ο Πανελλήνιο Συνέδριο Παθολογίας, Αθήνα, Οκτώβριος 2002 Δημοσίευση abstract – Νοσοκομειακά Χρόνια, Τόμος Περιλήψεων Εργασιών, Τόμος 64, Συμπλήρωμα 2002, #185, σ193, Οκτώβριος 2002

  8. Η αναστολή του πολλαπλασιασμού των λευχαιμικών κυττάρων HMC-1 με την παρουσία ρετινοϊκού οξέος συνοδεύεται από μειωμένη σύνθεση θρυπτάσης

    Αλεξανδράκης Μ, Ψυλλάκη Μ, Χριστοφορίδου Α, Σαριδάκη Ζ
    11ο Πανελλήνιο Αιματολογικό Συνέδριο της Ελληνικής Εταιρίας Αιματολογίας, Θεσσαλονίκη, Νοέμβριος 2000 1ο Βραβείο Αναρτημένης Ανακοίνωσης (Poster)

Σε Διεθνή Συνέδρια

  1. BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, prognostic and predictive values

    Z Saridaki, M Tzardi, M Sfakianaki, C Papadaki, K Mpananis, E Tsakalaki, M Trypaki, I Messaritakis, V Georgoulias, J Souglakos
    37th ESMO Congress, Vienna, Austria, September-October 2012 Accepted for publication in the ESMO 2012 Abstract Book, abstract ID 631

  2. PKM2 mRNA expression to predict disease recurrence in patients with stage II or III colon cancer treated with oxaliplatin in combination with fluoropyrimidines

    C Papadaki, M Sfakianaki, Z Saridaki, G Giagas, K Mpananis, M Tzardi, E Tsakalaki, M Trypaki, V Georgoulias, I Souglakos
    2012 ASCO Gastrointestinal Cancers Symposium
    Journal of Clinical Oncology Supplement, 30: 2012 (suppl 4; abstr # 468 (General Poster Session)

  3. Folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus chemoradiation (CRT) with 5-fluorouracil (5FU) as adjuvant treatment for patients with operable gastric cancer (OGC): A feasibility study with pharmacogenetic analysis

    A Athanasiadis, I Boukovinas, M Sfakianaki, Z Saridaki, C Papadaki, M Tzardi, N Androulakis, A Polyzos, V Georgoulias, I Souglakos
    2011 ASCO Gastrointestinal Cancers Symposium
    Journal of Clinical Oncology Supplement, 29: 2011 (suppl 4; abstr # 44 (General Poster Session)

  4. Impact of KRAS, BRAF and PIK3CA mutations, PTEN, AREG and EREG expression and skin rash in metastatic colorectal cancer patients treated with cetuximab-containing salvage treatment

    Z Saridaki, M Tzardi, C Papadaki, M Sfakianaki, F Pega, A Kalykaki, E Tsakalaki, D Mavroudis, V Georgoulias, I Souglakos
    2011 ASCO Gastrointestinal Cancers Symposium
    Journal of Clinical Oncology Supplement, 29: 2011 (suppl 4; abstr # 445 (General Poster Session)

  5. PKM2 as a biomarker for sensitivity to oxaliplatin-based chemotherapy in metastatic colorectal cancer (mCRC)

    C Papadaki, Z Saridaki, M Tzardi, M Sfakianaki, G Sfakiotaki, M Trypaki, I Messaritakis, D Mavroudis, V Georgoulias, I Souglakos
    2011 ASCO Gastrointestinal Cancers Symposium
    Journal of Clinical Oncology Supplement, 29: 2011 (suppl 4; abstr # 434 (General Poster Session)

  6. Vinorelbine metronomic plus bevacizumab as salvage therapy for patients with metastatic breast cancer (MBC): A multicenter phase II study

    E S Saloustros, K Kalbakis, N Vardakis, A Kalykaki, G Milaki, M Rovithi, S Agelaki, Z Saridaki, V Georgoulias, D Mavroudis
    2010 ASCO Annual Meeting
    Journal of Clinical Oncology Supplement, 28:15S, 2010 #1133 (General Poster Session)

  7. Use of BRAF mutations, microsatellite instability status, and cyclin D1 expression to predict metastatic colorectal (mCRC) patients' outcome

    I Sougklakos, Z Saridaki, M Tzardi, D Papadatos-Patsos, E Bairaktari, H Arvanity, E Stathopoulos, V Georgoulias, D Mavroudis
    ASCO 2010 Gastrointestinal Cancers Symposium, Orlando, Florida, USA, January 2010, General Poster Session C: Cancers of the Colon and Rectum Abstract No 355

  8. Prognostic and predictive significance of BRAF mutation in patients with metastatic colorectal cancer treated with 5-fluorouracil-based 1st line chemotherapy

    Z Saridaki, M Tzardi, D Papadatos-Patsos, E Kampouraki, E Zois, E Stathopoulos, V Georgoulias, D Mavroudis, J Souglakos
    Joint ECCO 15-34th ESMO Multidisciplinary Congress, Berlin, September 2009
    European Journal of Cancer Supplements, Volume 7 No 2, Abstract No 1016, p91, September 2009

  9. A multicenter phase I trial of Gemcitabine, Docetaxel and Carboplatin administered every 2 weeks as first line treatment in patients with metastatic breast cancer

    V Bozionelou, M Ignatiadis, Z Saridaki, A Karampeazis, G Sfakiotaki, A Pallis, J Gioulbasanis, V Markos, V Georgoulias, D Mavroudis
    19th International Congress on Anti-Cancer Treatment, Paris, February 2008
    Abstract Book #PO 9, p158

  10. Sarcoidosis can imitate metastatic melanoma. Report of two cases

    Z Saridaki, A Koutsopoulos, G Maltezakis, A Gounaris, D Stamatiou, M Hatzikou, O Zoras
    18th International Congress on Anti-Cancer Treatment, Paris, February 2007
    Abstract Book #71, p371-372

  11. First line chemotherapy with docetaxel plus gemcitabine in elderly or poor performance status patients with advanced non-small cell lung cancer: The experience of the Hellenic Oncology Research Group (HORG)

    M Ignatiadis, K Kalbakis, N Vardakis, S Giassas, G Sfakiotaki, Z Saridaki, V Bozionelou, J Gioulbasanis, A Pallis, V Georgoulias
    ECCO 13 The European Cancer Conference, Paris, October-November 2005
    EJC, Abstract Book, Volume 3, No 2, #1150, p332, October 2005

  12. The docetaxel and gemcitabine combination as first line chemotherapy in elderly or poor performance status patients with advanced non-small cell lung cancer. The experience of the Hellenic Oncology Research Group (HORG)

    M Ignatiadis, K Kalbakis, N Vardakis, S Giassas, G Sfakiotaki, Z Saridaki, V Bozionelou, J Gioulbasanis, A Pallis, V Georgoulias
    11th World Conference on Lung Cancer, Barcelona, July 2005

  13. First line treatment with docetaxel and cisplatin in non-small cell lung cancer patients: A retrospective analysis

    Kentepozidis N, Agelaki S, Vamvakas L, Kotsakis A, Saridaki Z, Gioulbasanis J, Kalykaki A, Ignatiadis M, Sfakiotaki G, Mavroudis D
    11th World Conference on Lung Cancer, Barcelona, July 2005

  14. Cetuximab plus Xelox as salvage treatment for patients with metastatic colorectal cancer (CRC) relapsing after combination chemotherapy including Oxaliplatin (LOHP), Irinotecan (CPT-11) and 5-fluorouracil (5-FU) or Capecitabine (CAP)

    J Souglakos, N Androulakis, A Kalykaki, Z Saridaki, N Vardakis, K Kalbakis, L Vamvakas, S Agelaki, N Kentepozidis, S Giassas, D Mavroudis, V Georgoulias
    3rd International Symposium on Targeted Anticancer Therapies (TAT), Amsterdam, March 2005

  15. Phase I study of weekly docetaxel and liposomal doxorubicin in patients with advanced solid tumors

    Kouroussis Ch, Androulakis N, Vamvakas L, Kalykaki T, Spiridonakou S, Kentepozidis N, Saridaki Z, Xiropoulou E, Georgoulias V
    16th International Congress on Anti-Cancer Treatment, Paris, February 2005
    Proceeding Book p333

  16. Increase incidence of central nervous system (CNS) involvement for patients with breast cancer (BC) treated with Taxanes based chemotherapy

    J Souglakos, L Vamvakas, Z Saridaki, I Kazakou, A Pallis, K Kalbakis, A Kalikaki, V Bozionelou, V Georgoulias
    29th ESMO Congress, Vienna, October-November 2004
    Annals of Oncology, Abstract Book, Volume 15, Supplement 3, #114P, piii30, 2004

  17. A non-comparative study of gefitinib in combination with vinorelbine and oxaliplatin as salvage therapy in women with cisplatin sensitive and –refractory advanced ovarian cancer

    D Mavroudis, E Efstathiou, G Aravantinos, M Karina, A Polyzos, E Kastritis, A Kalykaki, Z Saridaki, M A Dimopoulos
    29th ESMO Congress, Vienna, October-November 2004
    Annals of Oncology, Abstract Book, Volume 15, Supplement 3, #487P, piii130, 2004

  18. A phase II study with XELOX as salvage treatment for patients with metastatic colorectal cancer (MCC) pretreated with FOLFIRI

    Ch Kouroussis, A Athanasiadis, S Giassas, S Spiridonakou, Z Saridaki, G Sfakiotaki, N Kentepozidis, I Makridis, L Hellis, C Mikropoulos, V Georgoulias
    5th Congress of the Balcan Union of Oncology, Belgrade, October 2004

  19. Combination of irinotecan (CPT-11) and gefitinib (ZD1839) for patients with metastatic colorectal cancer (MCC) refractory to irinotecan-based 1st line chemotherapy: a pilot phase II study

    I Souglakos, Z Saridaki, A Pallis, L Vamvakas, K Kalbakis, D Mavroudis, G Milaki, A Kotsakis, M Ignatiadis, V Georgoulias
    World Congress on Gastrointestinal Cancer, Barcelona, June 2004
    Abstract Book, #P89

  20. Preliminary results of a pilot phase II of chronomodulated FOLFOX as salvage treatment for pretreated patients with metastatic colorectal cancer (MCC)

    I Souglakos, N Androulakis, D Tsetis, Th Kokkinakis, D Mavroudis, Ch Kourousis, S Agelaki, K Kalbakis, Z Saridaki, V Georgoulias
    World Congress on Gastrointestinal Cancer, Barcelona, June 2004
    Abstract Book, #P87

  21. A phase I-II trial of gefitinib in combination with vinorelbine and oxaliplatin as salvage therapy in women with advanced ovarian cancer (AOC)

    D Mavroudis, E Efstathiou, A Polyzos, A Athanasiadis, G Milaki, E Kastritis, A Kalykaki, Z Saridaki, A Dimopoulos, V Georgoulias
    ASCO 40th Annual Meeting, New Orleans, June 2004
    Journal of Clinical Oncology Supplement, Volume 22, No 14S, #5020 (Poster Discussion), p454s, July 2004

  22. Phase I study of alternating Oxaliplatin (OXA) with Irinotecan (IRI) in combination with weekly Leucovorin (LV)-modulated continuous infusion 5-Fluoruracil (5-FU) in patients with gastrointestinal malignancies: Final results

    N Androulakis, A Kotsakis, N Kentepozidis, Z Saridaki, T Kokkinakis, N Katsougris, G Milaki, L Vamvakas, Ch Kouroussis, V Georgoulias
    15th International Congress on Anti-Cancer Treatment, Paris, February 2004

  23. Paclitaxel, carboplatin and gefitinib (Iressa, ZD1839) as first-line chemotherapy in patients with advanced breast cancer: a phase II study

    Fountzilas G, Pectasides D, Skarlos DV, Kalofonos HP, Papadimitriou C, Linardou H, Kalogera-Fountzila A, Saridaki Z, Briassoulis E, Papadopoulos S, Lambropoulos S, Kosmidis P, Razis E, Gogas H
    26th Annual San Antonio Breast Cancer Symposium, December 2003

  24. Microsatelite instability (MSI) status in 31 colorectal cancer patients treated with a triplet combination with irinotecan (CPT-11), oxaliplatin (L-OHP) plus bolus and infusional 5FU/Leucovorin (DeGramont regimen)-FOLFOXIRI- as first line treatment: correlation of allelic imbalance with clinical parameters and treatment outcomes

    Z Saridaki, J Souglakos, M Tzardi, M Peraki, D Mavroudis, V Georgoulias
    5th International Congress Perspectives in Colorectal Cancer, Barcelona, June 2003

  25. Phase I study of biweekly oxaliplatin (LOHP) alternating with irinotecan (CPT-11) in combination with weekly administration of leukovorin (LV) and continuous 5-fluoruracil (5-FU) infusion in patients with advanced solid malignancies

    J Souglakos, N Vardakis, A Pallis, N Androulakis, Ch Kouroussis, S Kakolyris, Z Saridaki, N Tzenakis, N Xenidis, V Georgoulias
    5th International Congress Perspectives in Colorectal Cancer, Barcelona, June 2003
    Abstract Book, #65, p126

  26. Recurrence of cryptococcal meningoencephalitis in a patient with idiopathic CD4+ T lymphocytopenia

    D Kofteridis, Z Saridaki, I Kazakou, I Mixaki, A Gikas
    13th European Congress of Clinical Microbiology and Infectious Diseases, Glasgow, May 2003
    Proceedings Clinical Microbiology and Infection Volume 9, Supplement 1, #P819, p184, 2003

  27. Mutations of p16INK4a and p14ARF Tumor Suppressor Genes in SCC of the Skin and Lack of Mutation in BCC

    U Zoras, Z Saridaki, T Liloglou, A Zafiropoulos, E Koumantaki, DA Spandidos
    56th Annual Cancer Symposium of the Society of Surgical Oncology (SSO), Los Angeles, March 2003
    Proceedings Annals of Surgical Oncology Volume 10, No 1, #P129, pS78-S79, January 2003

  28. Mutational analysis of the p16 gene in patients with squamous cell carcinoma of the skin

    Z. Saridaki, T. Liloglou, A. Zafiropoulos, E. Koumantaki, O. Zoras and D.A. Spandidos
    7th World Congress on Advances in Oncology and 5th International Symposium on Molecular Medicine, Hersonissos, October 2002
    Proceedings International Journal of Molecular Medicine Volume 10, Supplement 1, #413, pS83, October 2002

  29. Urinary tract infections in adults with diabetes mellitus

    D Kofteridis, E Papadimitraki, S Lazaridou, Z Saridaki, I Mixaki, I Kazakou, E Ganotakis
    12th European Congress of Clinical Microbiology and Infectious Diseases, Milan, April 2002
    Proceedings Clinical Microbiology and Infection Volume 8, Supplement 1, #P974, p214-215, 2002

  30. Neutropenia due to Coxiella Burnetii, Rickettsia Typhi and Brucella melitensis infection

    Kofteridis DP, Doukakis S, Kalikaki A, Saridaki Z, Kazakou I, Gikas A, Tselentis Y
    The 1st Neutropenia Network Conference, Heraklion, April 2001
    Abstract Book, #1, p2

  31. Tension-free surgical repair of inguinal hernia (I.H.) by using prosthetic materials (ePTFE Gore-tex Mycro Mesh)®

    Athanasakis H, Saridaki Z, Kafetzakis A, Prokopakis G, Vrahasotakis N, Xynos E, Halkiadakis G, Zoras O
    XXI International Congress of the European Hernia Society, Madrid, November 1999

  32. Loss of Heterozygosity in Basal Cell Carcinoma implies involvement of p16 and BRCA1 genes

    Saridaki Z, Zoras O, Koumantaki E, Spandidos DA
    52nd Annual Cancer Symposium of the Society of Surgical Oncology (SSO), Orlando Florida, March 1999
    Abstract Book, #118, p64

  33. 2. High frequency of loss of heterozygosity in human basal cell carcinoma of the skin implies the involvement of the p16 genes

    Saridaki Z, Koumantaki El, Zoras O, Spandidos DA
    3rd World Congress on Advances in Oncology and 1st International Symposium on Molecular Medicine, Hersonissos, October 1998
    Proceedings International Journal of Molecular Medicine Volume 2, Supplement 1, #272, p47, October 1998

  34. High frequency of Loss of Heterozygosity in Human Basal Cell Carcinoma of the skin implies the involvement of the p16 and BRCA1 genes

    Saridaki Z, Koumantaki El, Zoras O, Spandidos DA
    49th Congress of the Hellenic Biochemical and Biophysical Society, Heraklion 1998
    Newsletter of the Hellenic Biochemical and Biophysical Society